Finance

Most Volatile Biotech Stocks: IGI Laboratories (NYSEMKT:IG), 22nd Century Group (NYSEMKT:XXII), PharmAthene (NYSEMKT:PIP), Pacific Biosciences of California (NASDAQ:PACB)

IGI Laboratories, Inc. (NYSEMKT:IG), a New Jersey-based generic topical pharmaceutical company, today announced that it has appointed Damian Finio to its Board of Directors. Mr. Finio will serve as the new Chairman of the Company’s Audit Committee. IGI Laboratories, Inc. (NYSEMKT:IG) stock performance was -10.79% in last session and finished the day at $4.88. Traded volume was 447,080.00million shares in the last session and the average volume of the stock remained 323.94K shares. The beta of the stock remained 0.95. IGI Laboratories, Inc. (NYSEMKT:IG) insider ownership is 0.70%.

Firms such as 22nd Century Group Inc (NYSEMKT:XXII), which alters the biological make-up of tobacco plants, may be targets of interest for Philip Morris through product licensing rights for the company to purchase and control. 22nd Century Group Inc (NYSEMKT:XXII) dropped -9.37 percent to $3.00 Monday on volume of 525,489.00million shares. The intra-day range of the stock was $2.95 to $3.36. 22nd Century Group Inc (NYSEMKT:XXII) has a market capitalization of $174.76million.

PharmAthene, Inc. (AMEX:PIP) announced that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax anthrax vaccine contract through a partial termination for convenience. PharmAthene, Inc. (NYSEMKT:PIP)’s stock on Apr 07, 2014 reported a decrease of -4.09% to the closing price of $1.64. Its fifty two weeks range is $1.47 -$2.42. The total market capitalization recorded $87.84million. The overall volume in the last trading session was 613,386.00million shares. In its share capital, PIP has 53.57million outstanding shares.

Pacific Biosciences of California (NASDAQ:PACB) will hold its quarterly conference call to discuss its First Quarter 2014 Financial Results on Wednesday, April 30, 2014, at 4:30pm Eastern Time. On Monday, shares of Pacific Biosciences of California (NASDAQ:PACB) advanced 4.76% to close the day at $4.84. Company return on investment (ROI) is -91.00% and its monthly performance is recorded as -27.44%. Pacific Biosciences of California (NASDAQ:PACB) quarterly revenue growth is -1.63%.